Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06050733 · ClinicalTrials.gov registry record

The Gut Microbiome and Immunotherapy Response in Solid Cancers

A clinical trial of Cancer, sponsored by The University of Texas Medical Branch, Galveston.

Recruiting
Registry status
16
Enrollment target
1
Study location

NCT06050733 is a study of Cancer that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 16 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06050733, a study of Cancer, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.

RECRUITING
Registry status
16 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.

Conditions Studied

Study Locations (1)

Texas

  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2023-06-30
Est. Completion 2026-12-30

What the Registry Record Tells You About NCT06050733

The ClinicalTrials.gov registry entry for NCT06050733 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT06050733 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06050733 about?

NCT06050733 is a clinical study titled "The Gut Microbiome and Immunotherapy Response in Solid Cancers". The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.

What is the current status of trial NCT06050733?

This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2023-06-30. Estimated completion is 2026-12-30.

What conditions does trial NCT06050733 study?

This clinical trial studies the following conditions: Cancer.

Who is sponsoring clinical trial NCT06050733?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06050733 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.